<DOC>
	<DOCNO>NCT02651194</DOCNO>
	<brief_summary>The purpose study assess efficacy safety 12 week treatment ABT-493/ABT-530 combination regimen adults chronic HCV genotype 1 - 6 infection chronic renal impairment .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety ABT-493/ABT-530 Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Chronic hepatitis C virus ( HCV ) infection Screening laboratory result indicate HCV genotype 1 6 ( GT1 6 ) infection . Subject must HCV treatmentnaïve fail previous HCV treatment . Subjects underlie chronic renal impairment Noncirrhotic subject must document absence cirrhosis subject cirrhosis must document compensated cirrhosis . History severe , lifethreatening significant sensitivity excipients study drug . Female pregnant , plan become pregnant study , breastfeed ; male whose partner pregnant planning become pregnant study . Recent ( within 6 month prior study drug administration ) history drug alcohol abuse could preclude adherence protocol opinion investigator . Positive test result Screening hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) . HCV genotype perform screen indicate coinfection 1 HCV genotype .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Treatment-naïve</keyword>
	<keyword>HCV Gentoype 6</keyword>
	<keyword>HCV Gentoype 1</keyword>
	<keyword>Compensated cirrhotic</keyword>
	<keyword>HCV Gentoype 2</keyword>
	<keyword>Treatment-experienced</keyword>
	<keyword>Non-cirrhotic</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HCV Gentoype 5</keyword>
	<keyword>HCV Gentoype 3</keyword>
	<keyword>HCV Gentoype 4</keyword>
</DOC>